{
  "id": 21078932,
  "title": "Eli Lilly's Next Big Growth Opportunity Could Be Hiding in Plain Sight",
  "url": "https://urgent.news/2026/11/21/eli-lillys-next-big-growth-opportunity-could-be-hiding-in-plain-sight",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-21T17:17:02.000Z",
  "source": {
    "name": "Motley Fool",
    "slug": "motley-fool",
    "url": "https://www.fool.com/investing/2026/11/21/eli-lilly-s-next-big-growth-opportunity-could-be-hiding-in-plain-sight/?source=iedfolrf0000001"
  },
  "original_language": "en",
  "account": "Eli Lilly (LLY -0.30%) recently reported a successful third-quarter earnings update, highlighting the continued growth potential of their top products, Mounjaro for diabetes and Zepbound for weight loss. While Zepbound is currently approved for adults aged 18 and older, with a BMI of 30 or more, or 27 with a weight-related comorbidity, Eli Lilly is actively conducting clinical trials to test its effectiveness in younger patients. The results of one such trial, involving participants aged 12 to 17, demonstrated that Zepbound led to an average weight loss of about 40 pounds, while those on a placebo gained an average of 5 pounds after 72 weeks. Additionally, BMI decreased by 18.5% in those who took Zebbound, compared to a 0.5% increase in the placebo group. If approved for this younger demographic, Zebbound could tap into a significant market of over five million potential patients in the U.S. alone, with an estimated $6.5 billion in annual net revenue. While there are challenges to consider, such as ramping up sales and facing competition from other GLP-1 drugs, Eli Lilly's proven track record and expanding pipeline make this a potentially lucrative opportunity.",
  "summary": "Lilly’s famous weight-loss drug may be about to get younger.",
  "key_points": [
    "Eli Lilly's Zepbound shows weight loss success in 12-17 year olds",
    "Potential market of over 5 million U.S. patients if approved",
    "$6.5 billion annual net revenue projected if Zepbound approved"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}